Obviously TPIV200/100/110 are not "dead" but you have to be ridiculously naive to believe that they will bring much value at this point in time compared to MultiTAA. Without the company coming out and explicitly stating it TPIV200/100/110 have essentially been tabled on their end.
Between them there is only one open trial sponsored by Marker which I would not be surprised to see terminated in the near future. The others are all sponsored by Mayo with DoD grants. This means we won't get news from Marker because they don't have any. Mayo will provide any updates as they see fit. That being said I would not expect many updates from them and would caution against using the timelines listed on clinicaltrials.gov as these are arbitrary dates and don't mean much in the grand scheme of things. They come and go on many trials with no updates given.
Market Data 
Markets 
AI
